Astex Pharmaceuticals, Inc.

Quick facts

Marketed products

• Treatment Choice · Oncology

Phase 3 pipeline

• Decitabine/Cedazuridine · Oncology
  Decitabine is a DNA methyltransferase inhibitor that causes hypomethylation of DNA, leading to reactivation of silenced tumor suppressor genes and differentiation of myelodysplastic cells.
• Treatment Choice (TC) · Oncology
  Treatment Choice (TC) is a small molecule that targets the CD47/SIRPα axis.

Phase 2 pipeline

• AT13387 and Imatinib · Oncology
  AT13387 is a potent and selective inhibitor of the B-Raf V600E kinase, while Imatinib is a tyrosine kinase inhibitor targeting BCR-ABL, c-Kit, and PDGFR.
• AT7519M · Oncology
  AT7519M is a potent inhibitor of the JAK2 protein.

Phase 1 pipeline

• ASTX727 Dose Confirmation
• ASTX727 Dose Escalation
• ASTX727 Fixed-Dose Combination
• MP-470

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Astex Pharmaceuticals, Inc. portfolio CI brief
• Astex Pharmaceuticals, Inc. pipeline updates RSS